The dead-donor rule and the future of organ donation.

Abstract

1287 cular risks of rosiglitazone led to a major change in FDA policy regarding the approval of all new diabetes drugs. From a cardiovascular perspective, rosiglitazone, saxagliptin, and alogliptin appear to be relatively safe. It is disappointing, however, that neither intensive glycemic control nor the use of specific diabetes medications is associated… (More)
DOI: 10.1056/NEJMp1307220

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Blog articles referencing this paper

Slides referencing similar topics